Rainbow Coral Corp. (RBCC) Shares Excitement as TheraKine Joint Venture Moves Forward
Rainbow Coral this morning told investors that it is already searching for new targets that would benefit from adding licenses for the drug delivery protocols TheraKine and RBCC plan to roll out. TheraKline, developer of a revolutionary drug delivery platform that could soon make local delivery of biologic agents and small molecules safer and more effective, joint ventured with RBCC’s biotech subsidiary very recently. As noted in today’s press release, the global market for drug delivery technologies is driven by biologics and medications that can’t be administered effectively through traditional means. It is believed by some experts that the worldwide…